ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

mRNA Seasonal Flu vaccine

In GlaxoSmithKline’s pipeline, mRNA vaccine. Its studies are mostly in Influenza, Human, led by GlaxoSmithKline.

Furthest: phase 3, since Sep 1, 20262 company-led studies, 2 open or runningNext primary completion: Jul 9, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
GlaxoSmithKline22 open or runningphase 3since Sep 1, 2026Sep 1, 2026Jul 9, 2027phase 3 · NCT07851246

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 1, 2026First studies: 2 phase 3 studies in Influenza, HumanFirst studyNCT07805707, NCT07851246

Ahead

  1. Jul 9, 2027Primary completion: phase 3 study in Influenza, HumanNCT07851246
  2. Jun 9, 2028Primary completion: phase 3 study in Influenza, HumanNCT07805707

TargetBeta

A vaccine: it acts on a pathogen, not a human gene.

“mRNA vaccine”the company's pipeline, read by Claude · source
“mRNA Seasonal Flu vaccine”name, by rule

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07851246Influenza, Human · United States3RecruitingJul 9, 20273,000
NCT07805707Influenza, Human · United States3RecruitingJun 9, 202854,000

How it is read

Names in the registry

  • “mRNA Seasonal Flu vaccine”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.